{"protocolSection": {"identificationModule": {"nctId": "NCT00628758", "orgStudyIdInfo": {"id": "D5890L00016"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Comparison of Symbicort\u00ae Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma", "officialTitle": "A Comparison of Symbicort\u00ae Single Inhaler Therapy (Symbicort Turbuhaler\u00ae 160/4.5mg, 1 Inhalation Two Times a Day (b.i.d.) Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults a -26-week, Randomized, Open-label, Parallel-group, Multicentre Study", "acronym": "PASSION"}, "statusModule": {"statusVerifiedDate": "2012-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-12"}, "primaryCompletionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-01-10", "studyFirstSubmitQcDate": "2008-02-25", "studyFirstPostDateStruct": {"date": "2008-03-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-09-18", "resultsFirstSubmitQcDate": "2012-07-06", "resultsFirstPostDateStruct": {"date": "2012-08-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-07-06", "lastUpdatePostDateStruct": {"date": "2012-08-14", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adult patients with persistent asthma.", "detailedDescription": "A secondary objective is to collect safety data for treatment wtih Symbicort Single inhaler Therapy in adult patients with persistent asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Symbicort", "Turbuhaler", "Persistent Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 430, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Symbicort", "type": "EXPERIMENTAL", "description": "Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)", "interventionNames": ["Drug: Symbicort TBH - Turbuhaler"]}, {"label": "Conventional BP", "type": "EXPERIMENTAL", "description": "Conventional Best Practice for Treatment of Asthma", "interventionNames": ["Drug: beta-II-agonist, inhale steroid"]}], "interventions": [{"type": "DRUG", "name": "Symbicort TBH - Turbuhaler", "description": "Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)", "armGroupLabels": ["Symbicort"]}, {"type": "DRUG", "name": "beta-II-agonist, inhale steroid", "description": "Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage", "armGroupLabels": ["Conventional BP"], "otherNames": ["Astmerol inh 25 mcg/dosage, 60-120 dosage", "Astmerol maksihaler 50 mcg/dosage, 28-60 dosage", "Serevent diskus 50 mcg/dosage, 60 dosage", "Serevent inh 25 mcg/dosage, 60 dosage", "Foradil inh kap 12 mcg/dosage, 60 caps", "Foradil inh 12 mcg/dosage, 50-100 dosage", "Foradil combi 200 mcg", "Foradil combi 400 mcg", "Oxis turbuhaler 4.5-9 mcg/dosage, 60 dosage", "Ventofor 12mg/60 inh.caps", "Seretide disc 100-250-500 mcg/dosage 60 dosage", "Symbicort 160/4.5 mcg/60-120 dosage, 320/9mcg/60 dosage"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Time to First Severe Asthma Exacerbation", "description": "Time to severe exacerbation among patients", "timeFrame": "26 weeks"}], "secondaryOutcomes": [{"measure": "Number of Severe Asthma Exacerbations", "description": "Total number of severe asthma exacerbations per treatment group", "timeFrame": "26 weeks"}, {"measure": "Change in Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) Score", "description": "Quality-of-Life assessment; grouped in four domains;activity limitation, symptoms, emotional function and exposure to environmental stimuli, using with a scale from 1 to 7 where 1 represents the greatest possible impairment and 7 represents the least impairment.", "timeFrame": "Baseline and 26 weeks"}, {"measure": "Mean Use of As-needed Medication Per Day During Treatment Period", "description": "Mean use of as-needed medication per day during treatment period", "timeFrame": "Daily recording during the treatment period of 26 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent form. If the patient cannot read and write, verbal consent from the patient is required.\n* Ability to read and write in Turkish\n* Female or male outpatients aged 18 years\n* Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society (ATS) definition\n* Prescribed inhaled glucocorticosteroid (GCS) at a dose of 320mg/day and within the approved label for the relevant drug during the last 3 months prior to Visit 1\n* Either: daily maintenance treatment with both inhaled GCS and long-acting b2-agonist (LABA) or daily treatment with inhaled GCS alone (i.e. without LABA); and a history of suboptimal asthma control the month prior to enrollment as judged by the investigator; and use of 3 Peak Expiratory Flow inhalations ofas needed medication for symptom relief during the last 7 days before enrollment\n\nExclusion Criteria:\n\n* Previous treatment with Symbicort Single inhaler Therapy\n* Use of any b-blocking agent, including eye drops\n* Use of oral GCS as maintenance treatment\n* Known or suspected hypersensitivity to study therapy or excipients\n* A history of smoking 10 pack years\n* Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator\n* Any significant disease or disorder, which, in the opinion of the investigator, may put the patient at risk because of participating in the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Zeynep Misirligil", "affiliation": "Ankara Univ. Med. Fac, Chest Disease Dept", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Ankara", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Research Site", "city": "Antalya", "country": "Turkey", "geoPoint": {"lat": 36.90812, "lon": 30.69556}}, {"facility": "Research Site", "city": "Bursa", "country": "Turkey", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}, {"facility": "Research Site", "city": "Denizli", "country": "Turkey", "geoPoint": {"lat": 37.77417, "lon": 29.0875}}, {"facility": "Research Site", "city": "Diyarbakir", "country": "Turkey", "geoPoint": {"lat": 37.91363, "lon": 40.21721}}, {"facility": "Research Site", "city": "Edirne", "country": "Turkey", "geoPoint": {"lat": 41.67719, "lon": 26.55597}}, {"facility": "Research Site", "city": "Eski?ehir", "country": "Turkey"}, {"facility": "Research Site", "city": "Istanbul", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Research Site", "city": "Izmir", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}, {"facility": "Research Site", "city": "Kocaeli", "country": "Turkey", "geoPoint": {"lat": 39.62497, "lon": 27.51145}}, {"facility": "Research Site", "city": "Malatya", "country": "Turkey", "geoPoint": {"lat": 38.35018, "lon": 38.31667}}, {"facility": "Research Site", "city": "Manisa", "country": "Turkey", "geoPoint": {"lat": 38.61202, "lon": 27.42647}}, {"facility": "Research Site", "city": "Mersin", "country": "Turkey", "geoPoint": {"lat": 36.79526, "lon": 34.61792}}, {"facility": "Research Site", "city": "Samsun", "country": "Turkey", "geoPoint": {"lat": 41.27976, "lon": 36.3361}}, {"facility": "Research Site", "city": "Zonguldak", "country": "Turkey", "geoPoint": {"lat": 41.45139, "lon": 31.79305}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "FSI: LSI: LSO: Center type: Research and Training Host, Chest Medicine and Internal Medicine 23 Clinics. Number of enrolled subjects: 432, randomized: 430, completed patients: 344 ( Arm A:165, Arm B 179)", "groups": [{"id": "FG000", "title": "Symbicort", "description": "Symbicort Single Inhaler Therapy ( Turbohaler 160/4.5 microg, 1 inh bid + as need)"}, {"id": "FG001", "title": "Conventional BP", "description": "Conventional Best Practice for Treatment of asthma"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "209"}, {"groupId": "FG001", "numSubjects": "221"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "165"}, {"groupId": "FG001", "numSubjects": "179"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "42"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "31"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Investigator Moved", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Treatment Failure", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Symbicort", "description": "Symbicort Single Inhaler Therapy ( Turbohaler 160/4.5 microg, 1 inh bid + as need)"}, {"id": "BG001", "title": "Conventional BP", "description": "Conventional Best Practice for Treatment of asthma"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "221"}, {"groupId": "BG002", "value": "430"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "44.28", "spread": "12.09"}, {"groupId": "BG001", "value": "45.17", "spread": "12.71"}, {"groupId": "BG002", "value": "44.7", "spread": "12.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "157"}, {"groupId": "BG001", "value": "179"}, {"groupId": "BG002", "value": "336"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "94"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Time to First Severe Asthma Exacerbation", "description": "Time to severe exacerbation among patients", "reportingStatus": "POSTED", "anticipatedPostingDate": "2009-09", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort Single Inhaler Therapy ( Turbohaler 160/4.5 microgram (microg), 1 inh bid + as need)"}, {"id": "OG001", "title": "Conventional Best Practice (BP)", "description": "Conventional Best Practice for Treatment of asthma"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "221"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "120.3", "spread": "47.0"}, {"groupId": "OG001", "value": "103.7", "spread": "32.7"}]}]}]}, {"type": "SECONDARY", "title": "Number of Severe Asthma Exacerbations", "description": "Total number of severe asthma exacerbations per treatment group", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Severe Exacerbations", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort Single Inhaler Therapy ( Turbohaler 160/4.5 microg, 1 inh bid + as need)"}, {"id": "OG001", "title": "Conventional BP", "description": "Conventional Best Practice for Treatment of asthma"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "221"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}]}]}, {"type": "SECONDARY", "title": "Change in Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) Score", "description": "Quality-of-Life assessment; grouped in four domains;activity limitation, symptoms, emotional function and exposure to environmental stimuli, using with a scale from 1 to 7 where 1 represents the greatest possible impairment and 7 represents the least impairment.", "populationDescription": "ITT analysis was performed. Being in line with the analysis description population and due to the description of the variable. This patient-reported outcome variable could only be calculated for patients who have baseline and visit 4 AQLQ data. The AQLQ was not filled in by all enrolled patients.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 26 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort Single Inhaler Therapy ( Turbohaler 160/4.5 microg, 1 inh bid + as need)"}, {"id": "OG001", "title": "Conventional BP", "description": "Conventional Best Practice for Treatment of asthma"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.98", "spread": "1.12"}, {"groupId": "OG001", "value": "3.97", "spread": "1.15"}]}]}]}, {"type": "SECONDARY", "title": "Mean Use of As-needed Medication Per Day During Treatment Period", "description": "Mean use of as-needed medication per day during treatment period", "populationDescription": "ITT analysis was performed. Being in line with the analysis description population and due to description of the variable which was based on the patient's estimate, this variable could only be calculated of the patients who had recorded at least one estimate on their dairies they had been asked to return to the investigator at the study visits.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "inhalations per day", "timeFrame": "Daily recording during the treatment period of 26 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "Symbicort Single Inhaler Therapy ( Turbohaler 160/4.5 microg, 1 inh bid + as need)"}, {"id": "OG001", "title": "Conventional BP", "description": "Conventional Best Practice for Treatment of asthma"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "178"}, {"groupId": "OG001", "value": "193"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.91", "spread": "7.6"}, {"groupId": "OG001", "value": "0.68", "spread": "5.7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Symbicort", "description": "Symbicort Single Inhaler Therapy ( Turbohaler 160/4.5 microg, 1 inh bid + as need)", "seriousNumAffected": 2, "seriousNumAtRisk": 209, "otherNumAffected": 0, "otherNumAtRisk": 209}, {"id": "EG001", "title": "Conventional BP", "description": "Conventional Best Practice for Treatment of asthma", "seriousNumAffected": 2, "seriousNumAtRisk": 221, "otherNumAffected": 0, "otherNumAtRisk": 221}], "seriousEvents": [{"term": "Cardiac Arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 221}]}, {"term": "Lower Limb Fracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 221}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 221}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 221}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com", "phone": "+44 1509 645895"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Cerebral Blood Flow", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Radiopharmaceutical", "relevance": "HIGH"}, {"id": "M16496", "name": "Terbutaline", "relevance": "LOW"}, {"id": "M21711", "name": "Budesonide", "relevance": "LOW"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}]}}, "hasResults": true}